Top 5 Stocks to Buy Now
→ Louis Navellier: My #1 AI stock for 2026 (name & ticker inside) (From InvestorPlace) (Ad)tc pixel Free ELYM Stock Alerts

Eliem Therapeutics (ELYM) Financials

Eliem Therapeutics logo
$12.18 +0.73 (+6.38%)
As of 06/22/2026
Compare
Annual Income Statements for Eliem Therapeutics

Annual Income Statements for Eliem Therapeutics

This table shows Eliem Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -23 -52 -45 -35 -74 -59
Consolidated Net Income / (Loss)		 -21 -47 -45 -35 -74 -60
Net Income / (Loss) Continuing Operations		 -21 -47 -45 -35 -74 -60
Total Pre-Tax Income 		-21 -47 -45 -35 -74 -60
Total Operating Income		 -21 -36 -45 -40 -82 -68
Total Gross Profit		 0.00 0.00 0.00 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 21 36 45 40 82 68
Selling, General & Admin Expense		 2.43 12 19 25 16 21
Research & Development Expense		 19 23 26 15 66 47
Total Other Income / (Expense), net		 0.26 -12 -0.11 5.16 8.12 8.03
Interest & Investment Income		 - - - - 8.13 8.32
Other Income / (Expense), net		 0.26 -12 - - -0.01 -0.29
Other Adjustments to Net Income / (Loss) Attributable to Common Shareholders)		 - - - - - -0.41
Basic Earnings per Share		 ($10.49) ($4.24) ($1.72) ($1.30) ($1.53) ($0.88)
Weighted Average Basic Shares Outstanding		 2.19M 12.26M 26.31M 26.99M 48.16M 67.81M
Diluted Earnings per Share		 ($10.49) ($4.24) ($1.72) ($1.30) ($1.53) ($0.88)
Weighted Average Diluted Shares Outstanding		 2.19M 12.26M 26.31M 26.99M 48.16M 67.81M
Weighted Average Basic & Diluted Shares Outstanding		 2.19M 12.26M 26.57M 27.72M 67.48M 47.77M

Quarterly Income Statements for Eliem Therapeutics

This table shows Eliem Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -3.97 -3.70 -1.70 -55 -8.69 -8.62 -21 -8.63 -13 -17 -14
Consolidated Net Income / (Loss)		 -3.97 -3.64 -1.70 -55 -8.90 -8.42 -21 -8.67 -13 -18 -14
Net Income / (Loss) Continuing Operations		 -3.97 -3.64 -1.70 -55 -8.90 -8.42 -21 -8.67 -13 -18 -14
Total Pre-Tax Income 		-3.97 -3.64 -1.70 -55 -8.90 -8.42 -21 -8.67 -13 -18 -14
Total Operating Income		 -5.00 -5.12 -3.01 -56 -12 -11 -23 -11 -15 -19 -15
Total Gross Profit		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 5.00 5.12 3.01 56 12 11 23 11 15 19 15
Selling, General & Admin Expense		 2.13 2.00 1.91 3.67 5.49 4.95 5.69 4.10 5.82 5.56 5.84
Research & Development Expense		 2.88 3.13 1.09 53 6.24 5.96 17 6.58 9.07 14 9.37
Total Other Income / (Expense), net		 1.03 1.48 1.31 1.48 2.84 2.50 2.24 2.01 2.00 1.78 1.49
Interest & Investment Income		 - - - 1.49 2.79 - 2.29 2.17 2.04 - 1.51
Other Income / (Expense), net		 - - - -0.00 0.05 - -0.05 -0.16 -0.03 - -0.03
Other Adjustments to Net Income / (Loss) Attributable to Common Shareholders)		 - - - - -0.20 - -0.26 -0.03 -0.15 - 0.28
Basic Earnings per Share		 - - ($0.06) ($1.81) ($0.13) $0.47 ($0.31) ($0.13) ($0.19) ($0.25) ($0.20)
Weighted Average Basic Shares Outstanding		 27.07M 26.99M 27.64M 30.35M 67.01M 48.16M 67.46M 67.59M 68.00M 67.81M 68.21M
Diluted Earnings per Share		 - - ($0.06) ($1.81) ($0.13) $0.47 ($0.31) ($0.13) ($0.19) ($0.25) ($0.20)
Weighted Average Diluted Shares Outstanding		 27.07M 26.99M 27.64M 30.35M 67.01M 48.16M 67.46M 67.59M 68.00M 67.81M 68.21M
Weighted Average Basic & Diluted Shares Outstanding		 27.07M 27.72M 29.09M 67.06M 67.22M 67.48M 67.58M 67.76M 68.18M 47.77M 57.26M

Annual Cash Flow Statements for Eliem Therapeutics

This table details how cash moves in and out of Eliem Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 7.38 26 -3.34 50 -5.88 -52
Net Cash From Operating Activities		 -14 -36 -37 -21 -16 -54
Net Cash From Continuing Operating Activities		 -5.63 -36 -37 -21 -16 -54
Net Income / (Loss) Continuing Operations		 -21 -47 -45 -35 -74 -60
Consolidated Net Income / (Loss)		 -21 -47 -45 -35 -74 -60
Depreciation Expense		 - - - - 0.00 0.10
Amortization Expense		 0.00 0.37 -0.18 -2.33 -0.76 -2.27
Non-Cash Adjustments To Reconcile Net Income		 13 18 7.78 13 57 8.27
Changes in Operating Assets and Liabilities, net		 2.29 -6.74 0.27 3.65 1.70 -0.60
Net Cash From Investing Activities		 8.08 -115 34 69 -121 2.83
Net Cash From Continuing Investing Activities		 8.08 -115 34 69 -121 2.83
Purchase of Property, Plant & Equipment		 - - - 0.00 0.00 -0.19
Acquisitions		 -0.20 - - - -4.65 0.00
Purchase of Investments		 0.00 -115 -88 -58 -132 -108
Sale and/or Maturity of Investments		 - 0.00 122 127 21 111
Other Investing Activities, net		 8.28 - - 0.00 -5.00 0.00
Net Cash From Financing Activities		 4.93 177 0.00 0.84 131 -0.02
Net Cash From Continuing Financing Activities		 4.93 177 0.00 0.84 131 -0.02
Repurchase of Common Equity		 - - - - 0.00 -0.09
Issuance of Common Equity		 0.00 83 0.00 0.84 120 0.00
Other Financing Activities, net		 - - - - 11 0.07
Effect of Exchange Rate Changes		 - 0.25 -0.41 0.30 0.04 0.00

Quarterly Cash Flow Statements for Eliem Therapeutics

This table details how cash moves in and out of Eliem Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 32 36 12 118 -77 -59 -58 -6.34 3.12 9.88 -27
Net Cash From Operating Activities		 3.49 -0.95 -1.82 -0.67 -7.56 -5.52 -15 -11 -12 -16 -14
Net Cash From Continuing Operating Activities		 3.49 -0.95 -1.82 -0.67 -7.56 -5.52 -15 -11 -12 -16 -14
Net Income / (Loss) Continuing Operations		 -3.97 -3.64 -1.70 -55 -8.90 -8.42 -21 -8.67 -13 -18 -14
Consolidated Net Income / (Loss)		 -3.97 -3.64 -1.70 -55 -8.90 -8.42 -21 -8.67 -13 -18 -14
Depreciation Expense		 - - - - - - 0.00 - 0.03 0.03 0.04
Amortization Expense		 -0.75 -0.35 -0.06 - -0.17 -0.53 -0.67 -0.57 -0.52 -0.51 -0.31
Non-Cash Adjustments To Reconcile Net Income		 2.38 1.62 0.60 52 2.82 1.75 2.09 1.07 4.03 1.10 1.68
Changes in Operating Assets and Liabilities, net		 5.83 1.42 -0.66 2.00 -1.31 1.67 3.93 -3.02 -2.79 1.27 -2.07
Net Cash From Investing Activities		 28 37 14 -9.65 -72 -53 -43 4.79 15 26 -13
Net Cash From Continuing Investing Activities		 28 37 14 -9.65 -72 -53 -43 4.79 15 26 -13
Purchase of Property, Plant & Equipment		 - - - - - - 0.00 - -0.11 - 0.00
Acquisitions		 - - - - - - 0.00 - - - 0.00
Purchase of Investments		 -2.46 -0.00 0.00 - -72 -60 -59 -21 -24 -5.00 -45
Sale and/or Maturity of Investments		 31 37 14 - - 7.00 16 25 39 31 32
Other Investing Activities, net		 - - - - - - 0.00 - - - 0.00
Net Cash From Financing Activities		 0.53 0.29 0.02 128 2.27 0.04 0.00 - - -0.02 0.01
Net Cash From Continuing Financing Activities		 0.53 0.29 0.02 128 2.27 0.04 0.00 - - -0.02 0.01
Issuance of Common Equity		 0.53 0.29 0.02 120 - - 0.00 - - - 0.00
Other Financing Activities, net		 - - - - 2.27 0.04 0.00 - - 0.07 0.01
Effect of Exchange Rate Changes		 0.00 -0.33 -0.03 0.02 0.11 -0.06 -0.02 0.02 - - 0.00

Annual Balance Sheets for Eliem Therapeutics

This table presents Eliem Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 25 173 135 110 217 168
Total Current Assets		 22 148 134 110 155 106
Cash & Equivalents		 20 47 44 93 87 36
Short-Term Investments		 0.00 90 80 14 64 65
Prepaid Expenses		 1.51 12 11 3.46 3.95 4.77
Plant, Property, & Equipment, net		 0.00 0.00 0.00 0.00 0.20 0.29
Total Noncurrent Assets		 2.63 25 0.60 0.21 62 62
Long-Term Investments		 0.00 25 0.00 0.00 62 60
Other Noncurrent Operating Assets		 2.63 0.07 0.60 0.21 0.51 2.04
Total Liabilities & Shareholders' Equity		 25 173 135 110 217 168
Total Liabilities		 3.06 6.04 6.28 2.87 5.31 7.27
Total Current Liabilities		 3.06 6.03 6.10 2.83 4.93 6.98
Accounts Payable		 1.29 1.40 0.75 0.07 0.71 2.27
Accrued Expenses		 1.22 4.63 5.05 2.43 4.07 4.46
Other Current Liabilities		 0.55 0.00 0.30 0.33 0.16 0.26
Total Noncurrent Liabilities		 0.00 0.01 0.18 0.04 0.38 0.29
Other Noncurrent Operating Liabilities		 - 0.01 0.00 0.04 0.38 0.29
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -25 167 129 108 212 160
Total Preferred & Common Equity		 -25 167 129 108 212 160
Total Common Equity		 -25 167 129 108 212 160
Common Stock		 3.15 243 250 264 442 450
Retained Earnings		 -28 -76 -121 -156 -230 -290
Accumulated Other Comprehensive Income / (Loss)		 0.00 -0.12 -0.36 -0.00 0.02 0.44

Quarterly Balance Sheets for Eliem Therapeutics

This table presents Eliem Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 116 113 109 226 222 201 192 182 152
Total Current Assets		 114 112 109 226 198 100 87 91 113
Cash & Equivalents		 25 57 105 223 146 29 23 26 8.36
Short-Term Investments		 77 50 0.00 0.00 47 69 62 61 101
Prepaid Expenses		 12 5.00 4.19 2.86 4.26 2.22 2.68 4.06 3.84
Plant, Property, & Equipment, net		 0.00 0.00 0.00 0.00 0.00 0.00 0.31 0.32 0.25
Total Noncurrent Assets		 2.03 0.30 0.11 0.02 25 100 105 91 39
Long-Term Investments		 - - - - 25 100 103 89 37
Other Noncurrent Operating Assets		 2.03 0.30 0.11 0.02 0.01 0.68 1.99 2.09 1.98
Total Liabilities & Shareholders' Equity		 116 113 109 226 222 201 192 182 152
Total Liabilities		 3.77 2.99 2.95 3.74 3.42 7.36 6.62 5.30 4.29
Total Current Liabilities		 3.62 2.90 2.95 3.74 3.42 7.04 6.21 4.95 4.07
Accounts Payable		 0.88 0.74 0.09 0.61 0.29 0.78 0.95 0.48 0.86
Accrued Expenses		 2.26 1.76 2.64 3.03 3.07 6.10 5.04 4.24 2.95
Other Current Liabilities		 0.49 0.40 0.23 0.10 0.06 0.16 0.22 0.23 0.26
Total Noncurrent Liabilities		 0.16 0.09 0.00 0.00 0.00 0.32 0.42 0.35 0.22
Other Noncurrent Operating Liabilities		 0.16 0.09 0.00 0.00 0.00 0.32 0.42 0.35 0.22
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 113 110 106 222 219 193 186 177 148
Total Preferred & Common Equity		 113 110 106 222 219 193 186 177 148
Total Common Equity		 113 110 106 222 219 193 186 177 148
Common Stock		 261 262 264 435 440 444 445 449 451
Retained Earnings		 -148 -152 -158 -213 -221 -251 -259 -272 -303
Accumulated Other Comprehensive Income / (Loss)		 -0.04 -0.01 0.00 0.00 0.20 0.29 0.32 0.47 0.16

Annual Metrics And Ratios for Eliem Therapeutics

This table displays calculated financial ratios and metrics derived from Eliem Therapeutics' official financial filings.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 0.00 26,554,316.00 26,567,681.00 27,572,664.00 67,223,760.00 68,184,435.00
DEI Adjusted Shares Outstanding		 0.00 26,554,316.00 26,567,681.00 27,572,664.00 67,223,760.00 68,184,435.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 -1.96 -1.70 -1.27 -1.10 -0.87
Growth Metrics		 - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 0.00% -127.94% 3.82% 5.97% -94.31% 15.02%
EBIT Growth		 0.00% -129.73% 4.94% 10.77% -103.67% 16.89%
NOPAT Growth		 0.00% -70.48% -26.53% 10.77% -103.65% 17.24%
Net Income Growth		 0.00% -129.73% 4.71% 22.38% -110.42% 19.01%
EPS Growth		 0.00% 59.58% 59.43% 24.42% -17.69% 42.48%
Operating Cash Flow Growth		 0.00% -155.87% -3.60% 44.88% 24.45% -249.29%
Free Cash Flow Firm Growth		 0.00% 0.00% -4.80% 23.96% -136.49% 14.25%
Invested Capital Growth		 0.00% 436.91% -8.18% -84.97% -180.90% 72.69%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% 0.00% 1.01% 9.53% -7.78% -13.86%
EBIT Q/Q Growth		 0.00% 0.00% 2.48% 9.91% -7.61% -14.58%
NOPAT Q/Q Growth		 0.00% 0.00% 2.48% 9.91% -7.59% -14.09%
Net Income Q/Q Growth		 0.00% 0.00% 5.79% 10.50% -6.91% -17.93%
EPS Q/Q Growth		 0.00% 0.00% -144.79% 0.00% 0.00% -450.00%
Operating Cash Flow Q/Q Growth		 0.00% -6.68% -1.54% 26.70% -41.63% -22.86%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 17.90% -7.83% -14.34%
Invested Capital Q/Q Growth		 0.00% 0.00% 11.51% -65.31% -176.33% -115.10%
Profitability Metrics		 - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 100.00% 100.00% 100.24% 87.20% 90.09% 87.79%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -95.83% -50.30% -30.58% -29.72% -46.26% -32.15%
Cash Return on Invested Capital (CROIC)		 0.00% -862.55% -559.05% -772.09% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 111.00% -37.90% -30.58% -29.72% -46.26% -32.15%
Return on Equity Simple (ROE_SIMPLE)		 82.73% -28.40% -35.15% -32.64% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -15 -25 -32 -28 -57 -48
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -29.39% -24.75% -9.59% -6.02% -10.32% -6.61%
Return On Investment Capital (ROIC_SIMPLE)		 - - - -26.20% -27.10% -29.61%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -21 -47 -45 -40 -82 -68
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -21 -47 -45 -43 -83 -70
Valuation Ratios		 - - - - - -
Price to Book Value (P/BV)		 0.00 1.66 0.76 0.69 0.57 1.70
Price to Tangible Book Value (P/TBV)		 0.00 1.66 0.76 0.69 0.57 1.70
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 93.49 20.05 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -0.95 -0.96 -0.96 -0.97 -1.00 -1.00
Leverage Ratio		 1.14 1.05 1.04 1.04 1.03 1.03
Compound Leverage Factor		 1.14 1.05 1.04 0.91 0.92 0.91
Debt to Total Capital		 0.00% 0.00% 0.14% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.14% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 215.83% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 -115.83% 100.00% 99.86% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 2.72 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 -0.01 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 3.91 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 -0.01 0.00 0.00 0.00
Altman Z-Score		 11.25 27.07 8.10 13.55 11.78 19.46
Noncontrolling Interest Sharing Ratio		 215.83% 24.66% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - -
Current Ratio		 7.18 24.58 22.04 38.92 31.41 15.16
Quick Ratio		 6.69 22.63 20.27 37.70 30.61 14.47
Cash Flow Metrics		 - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -30 -31 -24 -56 -48
Operating Cash Flow to CapEx		 0.00% 0.00% 0.00% 0.00% 0.00% -29,223.66%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - -
Invested Capital		 1.08 5.80 5.33 0.80 -0.65 -0.18
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 0.00 4.72 -0.48 -4.53 -1.45 0.47
Enterprise Value (EV)		 101 116 -26 -32 -92 112
Market Capitalization		 75 278 98 74 121 273
Book Value per Share		 ($11.42) $6.30 $4.84 $3.90 $3.15 $2.35
Tangible Book Value per Share		 ($11.42) $6.30 $4.84 $3.90 $3.15 $2.35
Total Capital		 22 167 129 108 212 160
Total Debt		 0.00 0.00 0.18 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.18 0.00 0.00 0.00
Net Debt		 -20 -161 -123 -107 -213 -161
Capital Expenditures (CapEx)		 0.00 0.00 0.00 0.00 0.00 0.19
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -1.55 5.74 4.73 0.62 -0.98 -2.22
Debt-free Net Working Capital (DFNWC)		 19 142 128 107 150 99
Net Working Capital (NWC)		 19 142 128 107 150 99
Net Nonoperating Expense (NNE)		 6.02 23 14 6.93 16 12
Net Nonoperating Obligations (NNO)		 -20 -161 -123 -107 -213 -161
Total Depreciation and Amortization (D&A)		 0.00 0.37 -0.18 -2.33 -0.76 -2.18
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - -
Adjusted Basic Earnings per Share		 $0.00 ($4.24) ($1.72) ($1.30) ($1.53) ($0.88)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 26.57M 26.31M 26.99M 48.16M 67.81M
Adjusted Diluted Earnings per Share		 $0.00 ($4.24) ($1.72) ($1.30) ($1.53) ($0.88)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 26.57M 26.31M 26.99M 48.16M 67.81M
Adjusted Basic & Diluted Earnings per Share		 $0.00 ($4.24) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 12.26M 26.57M 27.72M 67.48M 47.77M
Normalized Net Operating Profit after Tax (NOPAT)		 -15 -25 -32 -28 -57 -48
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% -0.14%

Quarterly Metrics And Ratios for Eliem Therapeutics

This table displays calculated financial ratios and metrics derived from Eliem Therapeutics' official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 27,089,240.00 27,572,664.00 27,719,409.00 29,091,166.00 67,060,163.00 67,223,760.00 67,475,395.00 67,575,767.00 67,764,100.00 68,184,435.00 47,767,980.00
DEI Adjusted Shares Outstanding		 27,089,240.00 27,572,664.00 27,719,409.00 29,091,166.00 67,060,163.00 67,223,760.00 67,475,395.00 67,575,767.00 67,764,100.00 68,184,435.00 47,767,980.00
DEI Earnings Per Adjusted Shares Outstanding		 -0.15 -0.13 -0.06 -1.89 -0.13 -0.13 -0.30 -0.13 -0.19 -0.25 -0.29
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 34.75% 45.07% 87.18% -656.19% -105.93% -109.14% -673.70% 79.76% -30.13% -72.94% 34.69%
EBIT Growth		 42.83% 46.39% 87.18% -739.65% -133.55% -113.02% -667.65% 80.77% -27.78% -76.85% 33.95%
NOPAT Growth		 42.83% 46.39% 87.18% -739.62% -134.59% -113.02% -665.99% 81.06% -26.93% -76.85% 33.92%
Net Income Growth		 59.02% 53.09% 92.39% -951.51% -124.17% -131.15% -1,124.57% 84.21% -44.89% -108.13% 33.97%
EPS Growth		 0.00% 0.00% 92.86% -852.63% 0.00% 0.00% -416.67% 92.82% -46.15% -153.19% 35.48%
Operating Cash Flow Growth		 183.59% 88.79% 88.01% 91.63% -316.48% -483.00% -748.49% -1,571.36% -60.68% -183.19% 6.84%
Free Cash Flow Firm Growth		 73.43% 115.17% 121.67% -311.31% -555.13% -756.56% -355.48% 76.69% -59.16% -125.87% -63.96%
Invested Capital Growth		 -51.68% -84.97% -81.93% -108.75% -63.23% -180.90% -429.64% -90.15% 38.04% 72.69% 139.91%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 22.82% 4.97% 43.89% -1,737.48% 78.98% 3.49% -107.56% 51.83% -35.14% -28.26% 21.61%
EBIT Q/Q Growth		 25.51% -2.42% 41.33% -1,776.01% 79.28% 6.58% -111.42% 52.91% -37.70% -29.29% 21.04%
NOPAT Q/Q Growth		 25.51% -2.42% 41.33% -1,775.94% 79.19% 7.00% -110.96% 53.61% -39.48% -29.57% 21.17%
Net Income Q/Q Growth		 23.98% 8.24% 53.39% -3,134.47% 83.79% 5.39% -146.92% 58.30% -48.72% -35.91% 21.66%
EPS Q/Q Growth		 0.00% 0.00% 0.00% -2,916.67% 92.82% 461.54% -165.96% 58.06% -46.15% -31.58% 20.00%
Operating Cash Flow Q/Q Growth		 143.82% -127.13% -92.08% 63.33% -1,032.68% 26.92% -179.55% 27.77% -8.89% -28.80% 8.03%
Free Cash Flow Firm Q/Q Growth		 85.24% 191.45% 327.70% -812.62% 76.50% 8.35% -66.43% 34.99% -60.51% -30.06% -20.81%
Invested Capital Q/Q Growth		 -76.60% -65.31% 68.91% -163.78% 198.38% -176.33% -588.27% 63.21% 171.42% -115.10% 1,105.65%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 79.34% 71.09% 56.47% 97.37% 76.16% 77.13% 90.09% 79.95% 86.35% 90.78% 90.06%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -32.15% -29.72% -13.01% -38.35% -42.08% -46.26% -62.04% -22.92% -25.65% -32.15% -30.92%
Cash Return on Invested Capital (CROIC)		 -813.34% -772.09% -175.42% 0.00% -3,287.00% 0.00% 0.00% 0.00% -4,153.55% 0.00% -2,713.10%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -32.15% -29.72% -13.01% -38.35% -42.08% -46.26% -62.04% -22.92% -25.65% -32.15% -30.92%
Return on Equity Simple (ROE_SIMPLE)		 -35.76% 0.00% -13.65% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -3.50 -3.59 -2.10 -39 -8.21 -7.64 -16 -7.47 -10 -14 -11
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -0.39% -0.05% 0.38% -9.47% -0.42% -0.49% -3.08% -0.58% -1.25% -2.15% -1.79%
Return On Investment Capital (ROIC_SIMPLE)		 - -3.33% -1.98% -17.75% -3.75% -3.60% -8.33% -4.02% -5.89% -8.42% -7.19%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -5.00 -5.12 -3.01 -56 -12 -11 -23 -11 -15 -19 -15
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -5.75 -5.47 -3.07 -56 -12 -11 -24 -11 -15 -20 -16
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.65 0.69 0.71 0.93 1.56 0.57 0.43 0.45 0.77 1.70 2.21
Price to Tangible Book Value (P/TBV)		 0.65 0.69 0.71 0.93 1.56 0.57 0.43 0.45 0.77 1.70 2.21
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 145.36 0.00 0.00 0.00 0.00 0.00 101.63
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -0.97 -0.97 -0.96 -0.97 -0.99 -1.00 -1.01 -1.01 -0.99 -1.00 -1.01
Leverage Ratio		 1.04 1.04 1.04 1.02 1.02 1.03 1.03 1.03 1.02 1.03 1.03
Compound Leverage Factor		 0.82 0.74 0.59 1.00 0.78 0.79 0.93 0.82 0.88 0.94 0.93
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 13.41 14.60 14.50 32.21 59.31 12.86 5.15 6.03 13.62 20.42 43.54
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 38.76 38.92 37.02 60.41 57.73 31.41 14.25 14.08 18.38 15.16 27.86
Quick Ratio		 37.03 37.70 35.60 59.65 56.49 30.61 13.94 13.65 17.56 14.47 26.91
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -1.03 0.94 4.03 -29 -6.75 -6.19 -10 -6.70 -11 -14 -17
Operating Cash Flow to CapEx		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -11,136.70% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 2.31 0.80 1.35 -0.86 0.85 -0.65 -4.46 -1.64 1.17 -0.18 1.78
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 -2.47 -4.53 -6.14 -11 -1.46 -1.45 -5.81 -0.78 0.32 0.47 6.24
Enterprise Value (EV)		 -36 -32 -29 -16 123 -92 -116 -104 -40 112 181
Market Capitalization		 71 74 76 207 341 121 82 84 136 273 327
Book Value per Share		 $4.05 $3.90 $3.84 $7.64 $3.26 $3.15 $2.87 $2.75 $2.61 $2.35 $3.10
Tangible Book Value per Share		 $4.05 $3.90 $3.84 $7.64 $3.26 $3.15 $2.87 $2.75 $2.61 $2.35 $3.10
Total Capital		 110 108 106 222 219 212 193 186 177 160 148
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -107 -107 -105 -223 -218 -213 -198 -187 -176 -161 -146
Capital Expenditures (CapEx)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.11 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 2.10 0.62 1.24 -0.88 0.84 -0.98 -4.82 -3.52 -0.89 -2.22 -0.23
Debt-free Net Working Capital (DFNWC)		 110 107 106 222 194 150 93 81 86 99 109
Net Working Capital (NWC)		 110 107 106 222 194 150 93 81 86 99 109
Net Nonoperating Expense (NNE)		 0.47 0.06 -0.41 15 0.68 0.78 4.67 1.19 2.46 4.01 3.07
Net Nonoperating Obligations (NNO)		 -107 -107 -105 -223 -218 -213 -198 -187 -176 -161 -146
Total Depreciation and Amortization (D&A)		 -0.75 -0.35 -0.06 0.00 -0.17 -0.53 -0.67 -0.57 -0.49 -0.48 -0.27
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.15) $0.00 ($0.06) ($1.81) ($0.13) $0.47 ($0.31) ($0.13) ($0.19) ($0.25) ($0.20)
Adjusted Weighted Average Basic Shares Outstanding		 27.07M 26.99M 27.64M 30.35M 67.01M 48.16M 67.46M 67.59M 68.00M 67.81M 68.21M
Adjusted Diluted Earnings per Share		 ($0.15) $0.00 ($0.06) ($1.81) ($0.13) $0.47 ($0.31) ($0.13) ($0.19) ($0.25) ($0.20)
Adjusted Weighted Average Diluted Shares Outstanding		 27.07M 26.99M 27.64M 30.35M 67.01M 48.16M 67.46M 67.59M 68.00M 67.81M 68.21M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 27.57M 27.72M 29.09M 67.06M 67.22M 67.48M 67.58M 67.76M 68.18M 47.77M 57.26M
Normalized Net Operating Profit after Tax (NOPAT)		 -3.50 -3.59 -2.10 -39 -8.21 -7.64 -16 -7.47 -10 -14 -11
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -0.14% 0.00%

Financials Breakdown Chart

Key Financial Trends

Climb Bio, Inc. (NASDAQ: CLYM) continues to look like a cash-rich, pre-revenue biotech, but the latest quarterly results also show that it is still burning through capital with no product revenue to offset expenses.

Top takeaways from the last several years:

  • The balance sheet remains strong despite losses, with $113.4 million in current assets at Q1 2026, including $8.4 million in cash and $101.2 million in short-term investments.
  • Climb Bio has virtually no debt, with only $4.3 million in total liabilities against $148.1 million in equity at Q1 2026.
  • The company continues to earn meaningful interest and investment income, which helped offset operating losses in recent quarters.
  • Cash and investments have remained substantial over the past year, giving the company runway to fund research and development.
  • The company is still a pre-revenue biotech; reported revenue was $0 in every quarter shown.
  • Operating cash flow is highly dependent on investment activity and changes in working capital, which can make quarterly cash flow look volatile.
  • Shares outstanding have remained elevated, which can dilute per-share value if future funding is needed.
  • Q1 2026 showed a net loss of $13.7 million, compared with a $17.5 million loss in Q4 2025 and $20.8 million in Q1 2025.
  • Operating cash flow was negative ($14.4 million) in Q1 2026, reflecting ongoing cash burn from the core business.
  • Research and development spending remains significant at $9.4 million in Q1 2026, while selling, general and administrative expenses added another $5.8 million.

Looking at the trend across the last four years, Climb Bio has steadily progressed from a smaller cash balance in 2023 to a much larger investment portfolio, while also scaling up operating expenses. That is a common profile for a clinical-stage biotech company: the business is prioritizing pipeline development over profitability.

The good news for investors is that the company appears to have a sizable liquidity cushion. The bad news is that it is still losing money each quarter, and there is no sign of commercial revenue yet. That means future stock performance will likely depend on clinical progress, financing decisions, and whether management can preserve enough capital to keep development moving forward.

06/23/26 10:16 PM ETAI Generated. May Contain Errors.

Eliem Therapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Eliem Therapeutics' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Eliem Therapeutics' net income appears to be on an upward trend, with a most recent value of -$59.85 million in 2025, rising from -$20.67 million in 2020. The previous period was -$73.90 million in 2024.

Eliem Therapeutics' total operating income in 2025 was -$67.88 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $67.88 million

Over the last 5 years, Eliem Therapeutics' total revenue changed from $0.00 in 2020 to $0.00 in 2025, a change of 0.0%.

Eliem Therapeutics' total liabilities were at $7.27 million at the end of 2025, a 37.0% increase from 2024, and a 137.3% increase since 2020.

In the past 5 years, Eliem Therapeutics' cash and equivalents has ranged from $20.49 million in 2020 to $93.11 million in 2023, and is currently $35.69 million as of their latest financial filing in 2025.

Over the last 5 years, Eliem Therapeutics' book value per share changed from -11.42 in 2020 to 2.35 in 2025, a change of -120.6%.


Related Companies

Financial statements for NASDAQ:ELYM last updated on 6/22/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
The roadshow starts Monday. This stock isn't ready.
The SpaceX roadshow kicks off June 8. Goldman Sachs, the lead underwriter, will present the full S-1 to the wo...
Behind the Markets | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
Do NOT Buy SpaceX – Do This Instead
SpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...
Stansberry Research | Sponsoredtc pixel
Trump just signed it
A recent policy development is drawing attention from income-focused investors. According to one analyst, c...
Investors Alley | Sponsoredtc pixel
SpaceX is chump change compared to Elon’s $20T ‘iPhone’
Early Apple investors saw peak gains as high as 7,537% after the iPhone launched. Now, multiple insider source...
StocksToTrade | Sponsoredtc pixel